Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riccardo Campi

Showing results (1-10 of 379) with videos related to

Pageof 38
Sort By:
European Urology|February 13, 2022
Predictive Models for Patients with a Renal Mass in the Clinical Trenches Continue to be a Muddy PropositionRiccardo Campi, Alexander Kutikov
European Urology|May 6, 2026
Re: Artificial Intelligence Tools Expand Scientists' Impact but Contract Science's FocusDavid D'Andrea, Riccardo Campi
Nature Reviews. Urology|April 29, 2026
Adjuvant immunotherapy for renal cell carcinoma: understanding complexity, embracing uncertainty, making a differenceRiccardo Campi, Daniele Amparore,
International Journal of Urology : Official Journal of the Japanese Urological Association|November 5, 2021
Editorial Comment to Randomized trials to determine the ideal management of the renal artery during partial nephrectomy: Life's under no obligation to give us what we expectRiccardo Campi, Daniele Amparore,
European Urology|March 19, 2019
Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort StudyRiccardo Campi, Morgan Roupret
Frontiers in Urology|August 8, 2025
Editorial: Rising stars in urologic oncology: 2021Juan Gómez Rivas, Riccardo Campi
European Urology|January 14, 2026
Re: Open Versus Robotic-assisted Partial Nephrectomy in Patients with Intermediate/High-complexity Kidney Tumours: Final Results of the Randomised, Controlled, Open-label, Multicentre Trial OpeRaDaniele Amparore, Eduard Roussel, Riccardo Campi, et al.
Current Opinion in Urology|April 10, 2024
Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern eraGiulio Francolini, Riccardo Campi, Chiara Ciccarese, et al.
Current Opinion in Urology|February 21, 2018
Relationship of surgeon/hospital volume with outcomes in uro-oncology surgeryPietro Grande, Riccardo Campi, Morgan Rouprêt
European Urology|December 10, 2021
Reply to Takeshi Takahashi's Letter to the Editor re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol 2021;80;760-2. Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki: Re-envisioning the Value of Clinical Research to Foster the Progress of Evidence-based Urology: The Case of Partial Nephrectomy for cT2 Renal MassesRiccardo Campi, Riccardo Bertolo, Andrea Minervini, et al.
Pageof 38

Showing results (1-10 of 379) with videos related to

Sort By:
Pageof 38
European Urology|February 13, 2022
Predictive Models for Patients with a Renal Mass in the Clinical Trenches Continue to be a Muddy PropositionRiccardo Campi, Alexander Kutikov
European Urology|May 6, 2026
Re: Artificial Intelligence Tools Expand Scientists' Impact but Contract Science's FocusDavid D'Andrea, Riccardo Campi
Nature Reviews. Urology|April 29, 2026
Adjuvant immunotherapy for renal cell carcinoma: understanding complexity, embracing uncertainty, making a differenceRiccardo Campi, Daniele Amparore,
International Journal of Urology : Official Journal of the Japanese Urological Association|November 5, 2021
Editorial Comment to Randomized trials to determine the ideal management of the renal artery during partial nephrectomy: Life's under no obligation to give us what we expectRiccardo Campi, Daniele Amparore,
European Urology|March 19, 2019
Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort StudyRiccardo Campi, Morgan Roupret
Frontiers in Urology|August 8, 2025
Editorial: Rising stars in urologic oncology: 2021Juan Gómez Rivas, Riccardo Campi
European Urology|January 14, 2026
Re: Open Versus Robotic-assisted Partial Nephrectomy in Patients with Intermediate/High-complexity Kidney Tumours: Final Results of the Randomised, Controlled, Open-label, Multicentre Trial OpeRaDaniele Amparore, Eduard Roussel, Riccardo Campi, et al.
Current Opinion in Urology|April 10, 2024
Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern eraGiulio Francolini, Riccardo Campi, Chiara Ciccarese, et al.
Current Opinion in Urology|February 21, 2018
Relationship of surgeon/hospital volume with outcomes in uro-oncology surgeryPietro Grande, Riccardo Campi, Morgan Rouprêt
European Urology|December 10, 2021
Reply to Takeshi Takahashi's Letter to the Editor re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol 2021;80;760-2. Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki: Re-envisioning the Value of Clinical Research to Foster the Progress of Evidence-based Urology: The Case of Partial Nephrectomy for cT2 Renal MassesRiccardo Campi, Riccardo Bertolo, Andrea Minervini, et al.
Pageof 38